Skip to content
For US Healthcare Professionals Patient Site
Picture of LEMTRADA patient Charles. Picture of LEMTRADA patient Charles.
Charles
23
Marshall, MN
pursuing a bachelor’s degree in management
“I was young and had active RMS when I partnered with a doctor who understood the urgency for me to get on the right treatment for me.”

DISEASE HISTORY

1 Year

since RMS diagnosis

PATIENT BACKGROUND

RMS Risk Factors

male, African American, incomplete recovery from relapses

RMS TREATMENT HISTORY

1 prior DMT:
1 injectable therapy
for 1 year

WHAT MOTIVATED YOU TO EXPLORE OTHER TREATMENT OPTIONS?

It seemed RMS was winning the war and I was having frequent relapses and not getting better. I was in college and I wasn’t willing to compromise my dreams.

WHY LEMTRADA?

My doctor suggested LEMTRADA. My mother and I educated ourselves on the trial data, and with the help of my doctor, I felt that I could manage all the requirements.

HOW DID YOU HANDLE ANY CONCERNS?

LEMTRADA has requirements, like the monthly labs and self-checks, so staying on top of those is critical. I was most worried about how the monitoring would impact my school schedule. After discussing every aspect of treatment with my doctor, I knew what to expect. Knowledge is power!

WHAT WOULD YOU TELL SOMEONE CONSIDERING LEMTRADA?

Be your own best advocate and never give up the search for a treatment plan that can work for you. Finding a treatment takes time and I am so thankful that I spoke up and found a doctor who was a great partner.

Are your patients interested in learning
more about LEMTRADA?

Download the full patient resource

INDICATION

LEMTRADA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, the use of LEMTRADA should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.

Limitations of Use: LEMTRADA is not recommended for use in patients with clinically isolated syndrome (CIS) because of its safety profile.

IMPORTANT SAFETY INFORMATION

WARNING: AUTOIMMUNITY, INFUSION REACTIONS, STROKE AND MALIGNANCIES

CONTRAINDICATIONS

LEMTRADA is contraindicated in patients:

WARNINGS AND PRECAUTIONS

Most Common Adverse Reactions

In controlled clinical trials, the most common adverse reactions (incidence ≥10% and >interferon beta-1a) with LEMTRADA vs interferon beta-1a were: rash (53% vs 6%), headache (52% vs 23%), pyrexia (29% vs 9%), nasopharyngitis (25% vs 19%), nausea (21% vs 9%), urinary tract infection (19% vs 8%), fatigue (18% vs 13%), insomnia (16% vs 15%), upper respiratory tract infection (16% vs 13%), herpes viral infection (16% vs 3%), urticaria (16% vs 2%), pruritus (14% vs 2%), thyroid gland disorders (13% vs 3%), fungal infection (13% vs 4%), arthralgia (12% vs 9%), pain in extremity (12% vs 9%), back pain (12% vs 8%), diarrhea (12% vs 6%), sinusitis (11% vs 8%), oropharyngeal pain (11% vs 5%), paresthesia (10% vs 8%), dizziness (10% vs 5%), abdominal pain (10% vs 5%), flushing (10% vs 4%), and vomiting (10% vs 3%).

Use in Specific Populations

Physicians are encouraged to report pregnancies by calling 1-800-745-4447, option 2. Antibodies, including anti-CD52 and autoantibodies, may be transferred from the mother to the fetus during pregnancy. Placental transfer of anti-thyroid antibodies resulting in neonatal Graves’ disease has been reported.

Safety and effectiveness in pediatric patients less than 17 years of age have not been established. Use of LEMTRADA is not recommended in pediatric patients due to the risks of autoimmunity and infusion reactions, stroke, and because it may increase the risk of malignancies.

Please see full Prescribing Information, including Boxed WARNING.

Indication

LEMTRADA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, the use of LEMTRADA should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.

Limitations of Use: LEMTRADA is not recommended for use in patients with clinically isolated syndrome (CIS) because of its safety profile.

IMPORTANT SAFETY INFORMATION

WARNING: AUTOIMMUNITY, INFUSION REACTIONS, STROKE AND MALIGNANCIES

  • LEMTRADA causes serious, sometimes fatal, autoimmune conditions such as immune thrombocytopenia and anti-glomerular basement membrane (anti-GBM) disease. Monitor complete blood counts with differential, serum
Alternate Text